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Abstract 
Background: Saccharomyces cerevisiae (baker’s yeast) has great potential as a whole-cell biocatalyst for multistep 
synthesis of various organic molecules. To date, however, few examples exist in the literature of the successful biosyn-
thetic production of chemical compounds, in yeast, that do not exist in nature. Considering that more than 30% of all 
drugs on the market are purely chemical compounds, often produced by harsh synthetic chemistry or with very low 
yields, novel and environmentally sound production routes are highly desirable. Here, we explore the biosynthetic 
production of enantiomeric precursors of the anti-tuberculosis and anti-epilepsy drugs ethambutol, brivaracetam, 
and levetiracetam. To this end, we have generated heterologous biosynthetic pathways leading to the production of 
(S)-2-aminobutyric acid (ABA) and (S)-2-aminobutanol in baker’s yeast.
Results: We first designed a two-step heterologous pathway, starting with the endogenous amino acid l-threonine 
and leading to the production of enantiopure (S)-2-aminobutyric acid. The combination of Bacillus subtilis threonine 
deaminase and a mutated Escherichia coli glutamate dehydrogenase resulted in the intracellular accumulation of 
0.40 mg/L of (S)-2-aminobutyric acid. The combination of a threonine deaminase from Solanum lycopersicum (tomato) 
with two copies of mutated glutamate dehydrogenase from E. coli resulted in the accumulation of comparable 
amounts of (S)-2-aminobutyric acid. Additional l-threonine feeding elevated (S)-2-aminobutyric acid production to 
more than 1.70 mg/L. Removing feedback inhibition of aspartate kinase HOM3, an enzyme involved in threonine 
biosynthesis in yeast, elevated (S)-2-aminobutyric acid biosynthesis to above 0.49 mg/L in cultures not receiving 
additional l-threonine. We ultimately extended the pathway from (S)-2-aminobutyric acid to (S)-2-aminobutanol by 
introducing two reductases and a phosphopantetheinyl transferase. The engineered strains produced up to 1.10 
mg/L (S)-2-aminobutanol.
Conclusions: Our results demonstrate the biosynthesis of (S)-2-aminobutyric acid and (S)-2-aminobutanol in yeast. 
To our knowledge this is the first time that the purely synthetic compound (S)-2-aminobutanol has been produced 
in vivo. This work paves the way to greener and more sustainable production of chemical entities hitherto inacces-
sible to synthetic biology.
Keywords: (S)-2-Aminobutyric acid, l-Homoalanine, (S)-2-Aminobutanol, Carboxylic acid reductase, l-Threonine, 
2-Ketobutyric acid, Metabolic engineering, Ethambutol
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Background
(S)-2-Aminobutyric acid (ABA), also known as l-homo-
alanine, is a non-proteinogenic α-amino acid, which is 
a chiral precursor for the enantiomeric pharmaceuti-
cals levetiracetam, brivaracetam, and ethambutol [1, 2]. 
Enzymatic synthesis of chiral (R)- or (S)-2-aminobutyric 
acid has been reached by resolution of racemic mix-
tures with acylase [3, 4] or amidases [5], and asymmet-
ric synthesis starting from 2-ketobutyric acid has been 
achieved using ω-transaminases [6, 7] or amino acid 
dehydrogenases [8]. Both (R)- and (S)-2-aminobutyric 
acid were also synthesized using an (R)- or (S)-selective 
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ω-transaminase and isopropylamine as co-substrate [9]. 
Biosynthesis of (S)-2-aminobutyric acid (starting from 
the amino acid l-methionine) has been shown by co-
immobilization of l-methionase and glutamate dehydro-
genase on polyacrylamide or chitosan [1].
In contrast to in vitro synthesis with purified enzymes, 
whole-cell biocatalysts offer the advantage of simple and 
economical upstream processing as overheads for cell 
lysis, purification, and addition of co-factors are redun-
dant. Low cost media and straightforward downstream 
processes further contribute to a more cost-effective 
production process. In  vivo synthesis of (S)-2-ABA has 
been achieved via two different methods: (1) kinetic 
resolution of racemic 2-aminobutyric acid mixture with 
d-amino acid oxidase and ω-transaminase [10], and (2) 
asymmetric synthesis from l-threonine [11]. The latter 
setup used five E. coli strains containing five different 
genes.
(S)-2-aminobutanol is an important chiral building 
block for the chemical synthesis of the bacteriostatic anti-
tuberculosis agent (S, S)-ethambutol [12]. Activity assays 
using Mycobacterium smegmatis have shown that the (S, 
S)-configured diastereomer of ethambutol [(S, S)-2,20-
(ethylenediimino)-di-butanol] has the highest activity 
compared to all other measured derivatives, and is about 
500 times more potent than the (R, R)-diastereomer [13]. 
As ethambutol shows ocular toxicity as a side effect [14], 
it is desirable to keep the therapeutic dose as low as pos-
sible. Therefore, it is crucial to apply the potent (S, S)-
configured diastereomer exclusively. Several approaches 
have been developed to achieve chemical synthesis of 
enantiopure (S, S) ethambutol; e.g. resolution of racemic 
(S)-2-aminobutanol [15, 16]; use of palladium to accom-
plish regio-and stereo-selective epoxide opening [17]; use 
of l-methionine as chiral starting material [18, 19]; and 
introduction of protection groups during synthesis [20, 
21].
The application of engineered microorganisms for 
production of chemical building blocks with very high 
enantiomeric purity may help to improve the supply with 
cost-efficient active pharmaceutical compounds and, 
in contrast to chemical synthesis, no additional steps or 
protection groups are necessary. Increasingly, metabolic 
engineering and biotechnology are providing sustainable 
and cost-efficient production of precursors for a variety 
of pharmaceuticals [22–25].
To our knowledge, (S)-2-aminobutyric acid has not 
been produced in Saccharomyces cerevisiae, and (S)-
2-aminobutanol has not yet been produced in any 
engineered microorganism. Here, we have explored 
the possibilities of using the well-known GRAS 
microorganism S. cerevisiae for biosynthesis of (S)-
2-aminobutyric acid and subsequent production of (S)-
2-aminobutanol. We demonstrate the in vivo production, 




We have expanded the metabolic capacity of S. cerevisiae 
to generate (S)-2-aminobutyric acid ((S)-2-ABA) by intro-
ducing two heterologous enzymatic steps. Biosynthesis 
of this non-natural amino acid starts via deamination of 
l-threonine into the achiral intermediate 2-ketobutyric 
acid. This keto acid becomes then aminated in a second 
enzymatic step to yield (S)-2-ABA (Fig. 1).
Yeast-endogenous enzymes CHA1 and/or ILV1 in 
principal can execute this first enzymatic step. Regula-
tion of the corresponding encoding genes occurs in part 
at the promoter level: to overcome this regulation the 
coding sequences have been functionally linked to con-
stitutive promoters. An alternative strategy using heter-
ologous enzymes for this first step was also employed. 
We selected three heterologous threonine deaminases 
derived from Escherichia coli, Bacillus subtilis, and Sola-
num lycopersicum.
Based on the results from Zhang and co-workers we 
selected three mutated glutamate dehydrogenases (two 
from S. cerevisiae and one from E. coli) for the second 
enzymatic step [26]. In addition, we assessed two differ-
ent leucine dehydrogenases (from B. cereus and B. flexus), 
and a valine dehydrogenase (from S. fradiae) as putative 
enzymes for the amination step from 2-ketobutyric acid 
to (S)-2-aminobutyric acid [8, 27].
In total 15 S. cerevisiae strains were constructed, con-
taining different combinations of threonine deaminases 
and dehydrogenases. Expressing yeast CHA1 under 





L-threonine 2-ketobutyric acid (S)-2-aminobutyric acid
Fig. 1 Pathway from l-threonine to (S)-2-aminobutyric acid
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together with one of three heterologous enzymes for 
the second step of the pathway, or together with any of 
the three mutated glutamate dehydrogenases, yielded an 
accumulation of 0.32 ± 0.01 mg/L (S)-2-ABA upon 24 h 
of culture (Fig. 2a, orange bars). Significant shorter pro-
duction times led to titers close to the limit of quantifi-
cation. A longer production time enhanced the amount 
of (S)-2-ABA. For practical reasons a time of 24  h was 
chosen. Chiral HPLC analysis revealed the resultant (S)-
2-ABA to be of high enantiopurity (Additional file 1: Fig-
ure S1).
A less pronounced increase in (S)-2-ABA production 
was observed when using E. coli threonine deaminase 

























































































































Fig. 2 Intracellular accumulation of (S)-2-aminobutyric acid in S. cerevisiae expressing different enzyme combinations. a Either two different threo-
nine deaminases (orange bars ScCHA1, green bars EcILVa) for the first step of the (S)-2-aminobutyric acid pathway were expressed in combination 
with either one of six heterologous enzymes for the second step of the pathway. Yeasts that did not express the pathway enzymes were included 
as control. b EcGDH’ for the second step of the pathway was expressed in combination with either one of five different threonine deaminases. 
Diamonds indicate OD600 after 24 h of growth (all data: mean ± SD, n = 3)
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As the mutated E. coli GDH (EcGDH’) yielded the highest 
concentrations of (S)-2-ABA in combination with both 
ScCHA1 and EcILVa, we chose EcGDH’ to analyze the 
effect of the threonine deaminases derived from E. coli, 
B. subtilis, and S. lycopersicum on (S)-2-ABA production. 
Combining ILVa from B. subtilis with EcGDH’ led to the 
highest amount of (S)-2-ABA (0.40  ±  0.02  mg/L (S)-2-
ABA, Fig.  2b). Expression of the heterologous enzymes 
had negligible effect on strain growth, as reflected by the 
relatively constant OD600 values after 24 h of culture.
Extension of the heterologous pathway for production 
of (S)‑2‑aminobutanol
Enantiopure (S)-2-aminobutanol is a building block for 
the synthesis of the tuberculosis drug ethambutol. The 
chirality of (S)-2-aminobutyric acid is defined by the 
amine group, which makes it a well-suited intermedi-
ate for the biosynthesis of (S)-2-aminobutanol. Carbox-
ylic acid reductases (CARs) and aldehyde reductases are 
enzymes that can perform the final enzymatic steps from 
(S)-2-aminobutyric acid to (S)-2-aminobutanol (Fig.  3) 
by reduction of the terminal carboxylic acid group of 
(S)-2-aminobutyric acid to an alcohol, leaving the stereo 
center of the molecule intact.
We expressed one of four different carboxylic acid 
reductases (CARs) in combination with either a phos-
phopantetheinyl-transferase (PPTase) from M. smegma-
tis (for M. smegmatis CAR), or the one from B. subtilis 
(SFP) for all other CARs. CARs, when expressed in yeast, 
require a PPTase for activity [28]. Expression of a heter-
ologous aldehyde reductase derived from E. coli in our 
strains facilitated reduction of the (S)-2-aminobutanal to 
the corresponding alcohol (Fig.  3). Initial supplementa-
tion with additional (S)-2-ABA (0.5 g/L) was tested, as we 
observed rather low production of (S)-2-ABA.
LC–MS analysis of pellets and supernatants from cells 
grown for 72 h in non-buffered conditions in shake flasks 
revealed quantifiable amounts of the target compound 
(S)-2-aminobutanol exclusively in the supernatant, and 
only in strains expressing the carboxylic acid reduc-
tase from Mycobacterium marinum (Fig.  4a, blue bar). 
Shorter production times led to titers of (S)-2-aminobu-
tanol below the limit of quantification.
Adjusting the culture medium to pH 7 boosted pro-
duction levels. The neutral pH resulted in a significant 
increase of (S)-2-aminobutanol production in strains 
expressing M. marinum CAR (MmCAR). In those strains, 
we determined approximately 1.5-fold more (S)-2-amin-
obutanol under pH-adjusted growth conditions. Moreo-
ver, the strain expressing CAR from Nocardia iowensis 
(NiCAR) produced (S)-2-aminobutanol in quantifiable 
amounts when buffered to pH  7 (Fig.  4a, green bars). 
Integration of all pathway genes, including the CAR from 
M. marinum and its accessory protein SFP, resulted in an 
approximate threefold higher level of (S)-2-aminobutanol 
production compared with episomal expression of the 
pathway genes (Fig. 4b, green bars). Even without (S)-2-
ABA supplementation, production levels of (S)-2-amin-
obutanol reached 0.45 ± 0.03 mg/L (Fig. 4b, red bars).
Increasing titers of (S)‑2‑aminobutyric acid
As (S)-2-aminobutyric acid is critical for production of 
(S)-2-aminobutanol, we focused on boosting the bio-
synthesis of this compound. To investigate the kinetic 
coupling of the two heterologous enzymatic steps of the 
(S)-2-ABA pathway, we first determined the amount of 
2-ketobutyric acid in strains previously analyzed for (S)-
2-ABA production (Fig. 2). Combining ScCHA1 with any 
of the six enzymes for the second step of the pathway does 
not lead to detectable amounts of 2-ketobutyric acid. In 
contrast, combining EcILVa with any of the six enzymes 
for the second enzymatic step resulted in 2-ketobutyric 
acid accumulation in the range of 0.1  mg/L, except for 
the combination EcILVa and ScGDH1′ where no 2-keto-
butyric acid could be detected (Fig.  5a). The highest 
accumulation of 2-ketobutyric acid (0.98  ±  0.03  mg/L) 
was observed with threonine deaminase (SlTD) from S. 
lycopersicum combined with EcGDH’ (Fig. 5b). We con-
cluded that in the case of the S. lycopersicum threonine 
deaminase, a more efficient enzymatic coupling between 
threonine deaminase and glutamate dehydrogenase may 
improve conversion of l-threonine to (S)-2-ABA.
Optimizing enzymatic coupling
Next, we sought to optimize biosynthetic titers through 
improved enzymatic coupling. First, we introduced an 
additional copy of a mutated glutamate dehydrogenase 
from E. coli and combined it with the deaminase derived 
from S. lycopersicum. This genetic modification lead 
to 1.4-fold more (S)-2-ABA (Fig.  6, orange bars). The 
carboxylic acid reductase
and PPTase aldehyde reductase
(S)-2-aminobutyric acid (S)-2-aminobutanol(S)-2-aminobutanal
Fig. 3 Pathway from (S)-2-aminobutyric acid to (S)-2-aminobutanol
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concentration of 2-ketobutyric acid (Fig. 6, blue bars) is 
slightly diminished in the strain expressing two copies 
of EcGDH’, indicating that: (1) increasing the enzymatic 
capacity of the second enzyme indeed improves coupling 
of the two heterologous enzymes, and (2) additional opti-
mization of coupling may further enhance (S)-2-ABA 
production.
Increasing (S)‑2‑aminobutyric acid production by feeding 
l‑threonine
l-Threonine is the starting molecule for enzymatic syn-
thesis of (S)-2-aminobutyric acid. The concentration 
of l-threonine in our synthetic complete (SC) medium 
is 76  mg/L. When measured intracellularly upon 24  h 
of shake flask growth, the intracellular concentration 
of l-threonine is about 1.5–3  mg/L l-threonine (not 
shown). We hypothesized that elevating the l-threonine 
concentration may well influence (S)-2-ABA production.
The addition of 1.0 g/L of l-threonine resulted in intra-
cellular concentrations of l-threonine of 13–15  mg/L 
(8  mg/L for the combination SlTD and EcGDH’) which 
led to 250 to 435% intracellular (S)-2-ABA produc-
tion in all evaluated strains (Fig.  7a). The effect is even 












































Fig. 4 Extracellular accumulation of (S)-2-aminobutanol in S. cerevisiae. a Yeasts were transformed with plasmids harboring the sequences encod-
ing a threonine deaminase and EcGDH’, in combination with different carboxylic acid reductases. PPTases were either from Mycobacterium smeg-
matis (for MsCAR) or from Bacillus subtilis (SFP) for all other CARs. The aldehyde reductase for the last step of the pathway was derived from E. coli. 
Engineered yeasts were incubated for 72 h in selective SC medium containing 0.5 g/L (S)-2-aminobutyric acid (+(S)-2-ABA). The medium was either 
buffered to pH 7 (green bars), or supplied unbuffered (blue bar). Supernatants were analyzed for (S)-2-aminobutanol production. b All five pathway 
genes (CAR from Mycobacterium marinum) were integrated into chromosome XI-2. Yeasts were incubated for 72 h in selective SC medium buffered 
to pH 7, and were either supplied with 0.5 g/L (S)-2-aminobutyric acid (green bars), or were grown without additional (S)-2-aminobutyric acid supply 
(red bars). Diamonds indicate OD600 after 72 h of growth (all data: mean ± SD, n = 3)
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(S)-2-ABA (up 300–710%) in threonine–fed strains (for 
absolute values see Additional file  1: Figure S2). Obvi-
ously l-threonine feeding impacts not only on endog-
enous accumulation of (S)-2-ABA but also on secretion 
of the compound. Additional l-threonine feeding leads 
to a significant elevation of intracellular 2-ketobutyric 
acid in the strain expressing S. lycopersicum threonine 
deaminase (4.6-fold, in comparison to the non-fed condi-
tions). The higher amounts of 2-ketobutyric acid did not 
translate into higher amounts of (S)-2-ABA, again sug-
gesting a bottleneck at the second enzymatic step. The 
absolute concentration of (S)-2-ABA in the best producer 






















































































































Fig. 5 Intracellular accumulation of 2-ketobutyric acid upon 24 h of growth in selective SC medium. a Two different enzymes for the first step of 
the (S)-2-aminobutyric acid pathway were expressed (ScCHA1 and EcILVa) in combination with either one of six heterologous enzymes for the 
second step of the pathway. In case ScCHA1 was expressed or yeasts were not engineered (control), accumulation of 2-ketobutyric acid was below 
the limit of quantification. b EcGDH’ for the second step of the pathway is expressed in combination with either one of five different threonine 
deaminating enzymes. Diamonds indicate OD600 after 24 h of growth (all data: mean ± SD, n = 3)
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Upregulation of l‑threonine metabolism in S. cerevisiae 
by mutating HOM3 or deletion of GLY1
Mutation of aspartate kinase HOM3
Saccharomyces cerevisiae can synthesize l-threonine via 
a pathway that starts with the amino acid l-aspartate, 
and involves five enzymes (HOM3, HOM2, HOM6, 
THR1, and THR4) that assemble the amino acid via the 
four intermediates l-4-aspartyl-phosphate, l-aspar-
tate-4-semialdehyde, l-homoserine, and O-phospho-
l-homoserine [29]. It is known that l-threonine inhibits 
aspartate kinase activity in S. cerevisiae [30] and several 
mutant strains that overproduce l-threonine have been 
isolated which all contained a mutation in the aspartate 
kinase gene HOM3 that led to insensitivity towards feed-
back inhibition [31, 32].
We introduced such a mutated HOM3 gene via a 2μ 
plasmid into our yeast strains. This led to 2.3-fold higher 
l-threonine concentrations in strains not expressing the 
(S)-2-ABA pathway genes, and to a 4.7-fold increase in 
strains expressing the pathway genes (Fig. 8a). The higher 
amount of intracellular l-threonine also boosted the con-
centration of intracellular (S)-2-ABA 1.5-fold (Fig.  8b). 
As the boost in (S)-2-ABA production upon expression 
of the mutated HOM3 variant is accompanied by an 
impaired growth, the relative accumulation of (S)-2-ABA 
compared to the number of yeast cells is even higher.
Deletion of threonine aldolase (GLY1)
We tried another strategy to enhance the concentra-
tion of l-threonine, the deletion of the gene encoding 
for l-threonine aldolase GLY1. This enzyme irrevers-
ibly converts l-threonine into l-glycine [33]. We deleted 
the entire open reading frame of the unique GLY1 locus 
on chromosome V. Our Δgly1 deletion strain was via-
ble, albeit with impaired growth characteristics as also 
described previously [34, 35]. Routinely we grew the 
Δgly1 deletion strain in medium that was supplied with 
0.75  g/L l-glycine in the medium. It was not critical 
whether the pre-culture was prepared in glycine-con-
taining medium or not. In both cases, the OD600 after 
55 h of growth in shake flasks reached values above 27. 
However, omitting l-glycine in the main culture led to a 
massive growth retardation (OD600 below 7), as shown 
in Fig. 9. Therefore, transformation of plasmids into the 
Δgly1 deletion strain and growth of the strains was rou-
tinely done in l-glycine supplemented medium. GLY1 
wildtype and Δgly1 deleted strains were transformed 
with two enzyme combinations, BsILVa +  EcGDH’ and 
SlTD + EcGDH’.
The deletion of GLY1 does not seem to have an 
effect on the amount of both extra- and intracellu-
lar l-threonine (Additional file  1: Figure S3), except for 
the SlTD  +  EcGDH’ strain, which produces roughly 
two times more l-threonine than the other strains. 
The elevated concentration of l-threonine in the 
SlTD  +  EcGDH’ Δgly1 deletion strain does not trans-
late into an elevated concentration of 2-ketobutyric 
acid or (S)-2-aminobutyric acid (Fig.  10). In strains 
expressing SlTD  +  EcGDH’ (both GLY1 wildtype and 
Δgly1 deletion strain) the amount of 2-ketobutyric acid 
exceeds 1.2 mg/L. The concentration of (S)-2-ABA does 
not exceed 0.3  mg/L in those strains. The concentra-
tion of 2-ketobutyric acid is significantly lower in the 
BsILVa  +  EcGDH’ strains, suggesting tight coupling of 
2-ketobutyric acid generation and subsequent conversion 
to (S)-2-aminobutyric acid, as observed previously.
Discussion
In this study, we describe: (1) the production of enantio-
pure (S)-2-aminobutyric acid in Saccharomyces cerevi-
siae by expressing two heterologous genes that convert 
l-threonine to (S)-2-aminobutyric acid; (2) the prolon-
gation of the pathway from (S)-2-aminobutyric acid to 
(S)-2-aminobutanol by expressing three additional het-
erologous genes. Both compounds are of considerable 



























Fig. 6 Intracellular accumulation of (S)-2-aminobutyric acid and 
2-ketobutyric acid in S. cerevisiae, expressing threonine deaminase 
SlTD, and one or two copies of mutated glutamate dehydrogenase 
EcGDH’. Yeasts expressing SlTD were co-transformed with either one 
or two copies of the mutated glutamate dehydrogenase derived 
from E. coli. Concentrations of (S)-2-aminobutyric acid (orange) and 
2-ketobutyric acid (blue) were analyzed in the yeast pellets upon 24 h 
of growth in batch culture. Diamonds indicate OD600 after 24 h of 
growth (all data: mean ± SD, n = 3)
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the chiral anti-epileptic drugs levetiracetam and brivar-
acetam, as well as for the production of the chiral anti-
tuberculosis drug ethambutol. The latter one figures on 
the WHO list of essential medicines.
Pathway to (S)‑2‑aminobutyric acid
We show that expression of B. subtilis threonine deami-
nase, combined with expression of a mutated form of 
E. coli glutamate dehydrogenase leads to the produc-
tion of 0.40  ±  0.02  mg/L of (S)-2-aminobutyric acid in 
shake flask-grown S. cerevisiae cells. The higher pro-
duction in E. coli achieved by Zhang and co-workers 
[26] is perhaps due to the special properties of the E. 
coli strain employed, which can produce 8  g/L l-thre-
onine from 30  g/L glucose. Nevertheless, we rational-



































































































































































Fig. 7 Impact of l-threonine feeding on accumulation of (S)-2-aminobutyric acid and 2-ketobutyric acid. Yeasts were transformed with the gene 
combinations indicated on the x-axis’. Clones were grown for 24 h in selective medium fed with 1.0 g/L l-threonine. a (S)-2-Aminobutyric acid 
amounts accumulating in l-threonine-fed yeasts, shown as a percentage of non-fed yeasts; orange squares: intracellular (S)-2-aminobutyric acid, red 
circle: extracellular (S)-2-aminobutyric acid. b Absolute intracellular concentrations of (S)-2-aminobutyric acid (orange bars) and 2-ketobutyric acid 
(blue bars) in l-threonine fed yeasts. Diamonds in b indicate OD600 after 24 h of growth (all data: mean ± SD, n = 3)
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(S)-2-aminobutanol production, as it displays higher 
robustness and considerable tolerance against harsh 
fermentation conditions. Yeast is also more resistant 
towards exposure to (S)-2-aminobutanol (Additional 
file  1: Figure S4). Moreover, the fermentation of yeasts 
is easily implemented into existing ethanol productions 
plants, and there are no issues with phage contamination. 





























































Fig. 8 a Intracellular l-threonine concentrations in yeasts expressing HOM3-R2. Yeasts, either engineered for (S)-2-aminobutyric acid production 
(BsILVa + EcGDH’), or non-engineered yeasts, were transformed with a 2µ plasmid harboring the sequence encoding for mutated HOM3 (HOM3-R2) 
or they were transformed with an empty plasmid (wt). Intracellular l-threonine concentrations were analyzed as described in “Methods”. Diamonds 
indicate OD600 after 24 h of growth (all data: mean ± SD, n = 3). b Intracellular (S)-2-aminobutyric acid concentrations in yeasts expressing HOM3-
R2. Yeasts engineered for (S)-2-aminobutyric acid production (BsILVa + EcGDH’) were transformed with a 2µ plasmid harboring the sequence 
encoding for mutated HOM3 (HOM3-R2) or they were transformed with an empty plasmid (wt). Intracellular (S)-2-aminobutyric acid concentrations 
were analyzed as described in “Methods”. Diamonds indicate OD600 after 24 h of growth (all data: mean ± SD, n = 3)



















0.75 g/L additional L-glycine
Fig. 9 Growth of Δgly1 deletion strain. Δgly1 deletion strains were grown in selective medium either containing additional glycine (0.75 g/L l-gly-
cine), or devoid of any additional glycine. Black pre-culture and main culture contain l-glycine, blue pre-culture contains no l-glycine, main culture 
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Fig. 10 Intracellular accumulation of 2-ketobutyric acid and (S)-2-aminobutyric acid in S. cerevisiae not expressing GLY1. Wildtype and Δgly1 dele-
tion yeast strains were either engineered for (S)-2-aminobutyric acid production (BsILVa + EcGDH’ or SlTD + EcGDH’), or they contained the empty 
plasmids (control). Concentrations of (S)-2-aminobutyric acid (orange bars) and 2-ketobutyric acid (blue bars) were analyzed in the yeast pellets upon 
24 h of growth in batch culture. Diamonds indicate OD600 after 24 h of growth (all data: mean ± SD, n = 3)
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as safe”) organism; thereby further facilitating industrial 
scale up.
We have explored a variety of strategies to increase 
the yield of (S)-2-ABA production in our yeast strains; 
first by evaluating the effect of adding a second copy of 
mutated glutamate dehydrogenase. When analyzing 
intracellular 2-ketobutyric acid concentrations we real-
ized that in yeasts containing the enzyme combinations 
threonine deaminase from S. lycopersicum and mutated 
glutamate dehydrogenase from E. coli, a considerable 
amount of 2-ketobutyric acid (0.98 ± 0.03 mg/L) was not 
converted to (S)-2-aminobutyric acid. This may be due to 
the relatively low Km value of this heterologous l-threo-
nine deaminase (SlTD: 0.25  mM, [36]). In contrast, the 
deaminase from E. coli has a Km of 11  mM (if AMP is 
present, otherwise it is 91 mM) [37], and the one from B. 
subtilis is 9.6 mM [38]. The amount of l-threonine gen-
erated in the strains after 24 h of growth in shake flasks 
reaches approximately 2 mg/L (~0.017 mM intracellular 
l-threonine). This low intracellular l-threonine concen-
tration can be more efficiently converted to 2-ketobutyric 
acid by SlTD as this deaminase has a lower Km than the 
other threonine deaminases.
It is expected that the obvious massive increase in pro-
duction of 2-ketobutyric acid by SlTD would lead to a 
substantial elevation of (S)-2-ABA accumulation, espe-
cially taking into account the relatively high Km (8.4 mM) 
of EcGDH’ [26]. As this was not the case, the enzy-
matic capacity of E. coli glutamate dehydrogenase was 
enhanced by expressing a second copy of this enzyme 
in the yeast. The modification elevated the amount of 
(S)-2-aminobutyric acid, but a considerable amount of 
2-ketobutyric acid remained. This indicates that produc-
tion of (S)-2-ABA may not be massively tunable, probably 
due to substrate inhibition of the E. coli dehydrogenase 
[39]. This hypothesis is further substantiated by the 
fact that in threonine fed strains expressing SlTD and 
EcGDH’, 2-ketobutyric acid production was elevated to 
above 4.54 ± 0.93 mg/L, without increasing intracellular 
(S)-2-aminobutyric acid accumulation.
Feeding with l-threonine elevated intracellular (S)-
2-ABA accumulation in strains expressing the enzyme 
combination BsILVa and EcGDH’ more than fourfold 
compared to non-fed strains.
The conversion yield of l-threonine to (S)-2-ABA (no 
additional l-threonine) was 36% compared to 22% with 
additional l-threonine in the medium, indicating that 
l-threonine is consumed by enzymatic and/or efflux 
reactions triggered by the elevated intracellular l-threo-
nine concentration.
Interestingly, in contrast to the non-fed strains, most 
of the de novo (S)-2-ABA was found in the supernatant, 
indicating that (S)-2-ABA was either actively secreted, 
or passively diffused. l-Threonine strongly induces 
the broad-specificity amino acid permease AGP1 [40, 
41], suggesting that this permease may not only medi-
ate uptake of l-threonine, but also increase (S)-2-ABA 
efflux. Another putative mediator of (S)-2-ABA efflux 
could be the internal-membrane transporter AQR1. This 
transporter is involved in excretion of excess amino acids 
by exocytosis [42], suggesting that it may also secrete 
(S)-2-ABA.
As feeding with l-threonine significantly boosted (S)-
2-ABA production, we hypothesized that upregulation 
of threonine anabolism may enhance generation of (S)-2-
ABA in our engineered strains.
The G425D mutation of aspartate kinase HOM3, pre-
viously described to abrogate feedback-inhibition, led to 
a significant boost of both intracellular l-threonine and 
(S)-2-aminobutyric acid. Recently, Mülleder et  al. ana-
lyzed the amino acid metabolome of S. cerevisiae upon 
systematic gene deletions [43]. They found that dele-
tion of FPR1 (a peptidyl-prolyl cis–trans isomerase) 
enhanced intracellular l-threonine by around 2.5-fold. 
This increase is in good accordance with our HOM3 
mutant, indicating that FPR1 may indeed regulate feed-
back inhibition of HOM3 as previously suggested [31, 
44]. l-Threonine and (S)-2-aminobutyric acid were also 
detected at higher extracellular levels upon expression of 
the mutated form of HOM3. Those data indicate that the 
endogenous l-threonine supply is indeed critical for (S)-
2-ABA production.
The l-threonine aldolase GLY1 of S. cerevisiae cata-
lyzes the cleavage of l-threonine into l-glycine and 
acetaldehyde. In contrast to expectations, no elevated 
l-threonine levels were detected in Δgly1 deletion 
strains. The comparable concentrations of l-threonine 
accumulated in wild type and Δgly1 deletion strains led 
us to conclude that feedback inhibitory mechanisms are 
active e.g. aspartate kinase HOM3. Our Δgly1 deletion 
strains showed strongly impaired growth characteristics 
compared to the wildtype strains (four to fivefold lower). 
These growth characteristics are similar to the ones pre-
viously reported [34], suggesting that GLY1 is important 
for l-glycine synthesis.
Pathway to (S)‑2‑aminobutanol
Here, we report production of the non-natural com-
pound (S)-2-aminobutanol in S. cerevisiae. The highest 
production levels were observed in strains expressing 
(apart from the enzymes forming the (S)-2-aminobu-
tyric acid pathway) M. marinum carboxylic acid reduc-
tase and an aldehyde reductase from E. coli. The level of 
0.42 ±  0.07  mg/L (S)-2-aminobutanol could be reached 
by buffering the growth medium to pH 7. Valli and co-
workers [45] demonstrated previously that yeast cells 
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grown at pH 7 are viable and adjust their endogenous pH 
accordingly. Furthermore, CARs work predominantly at 
basic pH conditions [46]. We hypothesized therefore that 
adjusting the culture medium to pH 7 would increase 
intracellular pH and lead to elevated activity of heterolo-
gous CARs. Our results support this hypothesis. Without 
pH adjustment of the surrounding medium, the extra-
cellular pH drops to pH 2.5 in stationary phase [45] that 
would correspond to an intracellular pH around 5, which 
is not suitable for CAR activity [46].
Interestingly, integration of the entire pathway into a 
single position of chromosome XI significantly enhanced 
production of (S)-2-aminobutanol, even though pro-
moters and terminators of the heterologous genes were 
identical to those used for episomal expression. Growth 
of strains expressing the plasmid-encoded pathway was 
however significantly lower than yeast strains expressing 
the genome-integrated pathway. These results indicate 
that plasmid maintenance is perhaps at the expense of 
heterologous pathway expression and product genera-
tion. However, strains expressing the pathway also dis-
played retarded growth. One explanation for impaired 
cellular growth and proliferation are the reductive modi-
fications of intracellular fatty acids or reduction of fatty 
acids that form parts of membrane lipids by CARs [46, 
47]. Ultimately, compartmentalization of the heter-
ologous pathway might be a valuable approach for effi-
cient orthologous production of this non-natural chiral 
compound.
Previous studies have demonstrated that substrates 
with an amine group at the α-position are scarcely 
accepted by carboxylic acid reductases [48], suggesting 
that production of (S)-2-aminobutanol may be further 
boosted by optimizing the substrate binding site of the 
carboxylic acid reductase.
Co‑factor supply in the pathway
Threonine deaminases are pyridoxal-5′-phosphate (PLP) 
dependent, with the PLP co-factor remaining in the active 
site and being regenerated during the reaction cycle [49]. 
In S. cerevisiae PLP levels are elevated when the yeasts 
are grown under thiamine deficient conditions as the 
synthesis of PLP is inhibited by the presence of thiamine 
[50]. Enhanced conversion in whole-cell biocatalysis 
experiments employing PLP-dependent ω-transaminases 
and addition of PLP or preceding growth in thiamine-
deficient medium have been shown [50, 51].
Most of the enzymes in the pathway to (S)-2-amin-
obutanol require NADPH. Elevated NADPH supply 
should boost production of (S)-2-aminobutyric acid and 
(S)-2-aminobutanol, as shown previously for several 
other cofactor-dependent enzymatic reactions [52–55]. 
NADPH is generated predominantly by the pentose 
phosphate pathway. A recent study has shown that over-
expression of glucose-6-phosphate dehydrogenase 
ZWF1, the enzyme that catalyzes the first step of the 
pentose phosphate pathway, or overexpression of NADH 
kinase POS5 leads to a higher of NADPH-dependent het-
erologous production of β-carotene in S. cerevisiae [56]. 
In future studies, we will use the described approaches to 
enhance the efficiency of the heterologous pathway.
Conclusions
We have successfully assembled a heterologous meta-
bolic pathway in S. cerevisiae to produce the non-pro-
teinogenic amino acid (S)-2-aminobutyric acid and the 
purely synthetic compound (S)-2-aminobutanol. To our 
knowledge (S)-2-aminobutanol has never previously 
been produced biosynthetically. Our studies expand the 
spectrum of synthetic biology towards the biosynthesis 




l-threonine, 2-ketobutyric acid, (R)- and (S)-aminobu-
tyric acid, (R) and (S)-2-aminobutanol were bought from 
Sigma-Aldrich Chemie AG (Steinheim, Germany). Yeast 
Extract Peptone (YPD) medium with 20 g/L glucose was 
used for growth of the wildtype strain prior to transfor-
mation and both bought from Sigma-Aldrich Chemie 
AG. Synthetic complete (SC) drop out medium (Forme-
dium LTD, Hustanton, England) with 6.7 g/L yeast nitro-
gen base without amino acids and ammonium sulfate 
(Sigma-Aldrich Chemie AG), and 20 g/L glucose (Sigma-
Aldrich Chemie AG) was used for pre- and main cul-
tures. LB medium for growth of E. coli was supplied from 
Carl Roth GmbH + Co. KG (Karlsruhe, Germany).
Primers, genes, and strains
Primers used in this study were supplied by Microsynth 
AG (Balgach, Switzerland) and are shown in Additional 
file  1: Table S1. Genes used in this study are listed in 
Table  1. Saccharomyces cerevisiae strains generated 
throughout this study are listed in Table  2. All yeast 
strains were stored in 25% glycerol at −80 °C.
Molecular biology
Plasmid DNA was prepared using the ZR Plasmid 
Miniprep-Classic Kit (Zymo Research Corp, Irvine, CA, 
USA). Competent E. coli NEB 10-β cells (New England 
Biolabs, Herts, United Kingdom) were used for all clon-
ing steps. Restriction enzymes were supplied from New 
England Biolabs (Herts, United Kingdom). T4 ligase was 
from Agilent (Santa Clara, CA, USA), and thermostable 
DNA polymerase iProof™ High-Fidelity was purchased 
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from BioRad (Hercules, CA, USA). dNTPs were from 
Roche Diagnostics GmbH (Mannheim, Germany). PCR 
reactions were performed in a FlexCycler2 (Analytik 
Jena AG, Jena, Germany) using the appropriate cycling 
conditions. PCR products were purified using the DNA 
Clean & Concentrator-5 Kit from Zymo Research Corp 
(Irvine, CA, USA). Accuracy of genetic constructs 
was verified by sequencing (Microsynth AG, Balgach, 
Switzerland).
Plasmid construction, gene deletion, and integration
Most of the genes used in this study were supplied in 
plasmids as yeast-codon optimized versions of the origi-
nal genes (GeneArt, Thermo Fisher Scientific, Waltham, 
MA, USA). Genes were released from the plasmids, sup-
plied by the manufacturer, by HindIII/SacII digestions 
prior to ligation into our pre-cut entry vectors. Our entry 
vectors contain different combinations of promoters and 
terminators, which are flanked by 60  bp homologous 
regions (“linkers”) that enable the assembly of multiple 
expression cassettes in  vivo by homologous recombina-
tion [57, 58]. Accessory entry vectors dispose of autono-
mously replicating sequences, centromere regions, and 
auxotrophic markers as described in Eichenberger et al. 
[59]. One-pot digestion of entry vectors by AscI releases 
the expression cassettes composed of (1) promoter-gene-
terminator flanked by 60 bp linkers at the 5′ and 3′ end; 
(2) selection marker URA3 flanked by 60  bp linkers at 
the 5′ and 3′ end; and (3) replication origin ARS/CEN 
flanked by 60 bp linkers at the 5′ and 3′ end); or, for inte-
gration, two 560 bp homologous regions flanked by 60 bp 
linkers at the 5′ and 3′ sites. Released fragments were 
then transformed into the strains as described in the next 
paragraph.
Amplification of the plasmids containing the carbox-
ylic acid reductase from Nocardia farcinica has been 
reported to be not feasible in E. coli (personal commu-
nication Esben H. Hansen). Therefore, the gene was 
ordered in two fragments, containing a 60  bp homolo-
gous region. The entire open reading frame was fused 
in vivo in yeast. Correct assembly was confirmed by PCR 
amplification and subsequent sequencing.
HOM3 was amplified from yeast genomic DNA in 
three parts. The three sequence stretches were fused by 
overlap extension PCR thereby removing the HindIII site 
and mutating glycine 425 to aspartic acid. The resulting 
entire PCR product was cut with HindIII and SacII, and 
inserted into a 2μ yeast expression plasmid.
Table 1 Expression cassettes and plasmids
Feature Plasmid type ORF origin Description Uniprot number Reference
pGPD1-ScCHA1-tCYC1 Entry vector Saccharomyces cerevisiae Threonine deaminase P25379 This study
pGPD1-EcILVa-tCYC1 Entry vector Escherichia coli Threonine deaminase P04968 [26]
pGPD1-SlTD-tCYC1 Entry vector Solanum lycopersicum Threonine deaminase P25306 [61]
pGPD1-ScILV1-tCYC1 Entry vector Saccharomyces cerevisiae Threonine deaminase P00927 This study
pGPD1-BsILVa-tCYC1 Entry vector Bacillus subtilis Threonine deaminase P37946 [26]
pPGK1-ScGDH1′-tADH2 Entry vector Saccharomyces cerevisiae Glutamate dehydrogenase (K74V/T177S) P07262 This study
pPGK1-ScGDH3′-tADH2 Entry vector Saccharomyces cerevisiae Glutamate dehydrogenase (K75V/T178S) P39708 This study
pPGK1-EcGDH’-tADH2 Entry vector Escherichia coli Glutamate dehydrogenase (K92V/T195S) P00370 [26]
pPGK1-BcLeuDH-tADH2 Entry vector Bacillus cereus Leucine dehydrogenase C2RD20 [8]
pPGK1-BfLeuDH-tADH2 Entry vector Bacillus flexus Leucine dehydrogenase A0A0L1MCT3 This study
pPGK1-SfValDH-tADH2 Entry vector Streptomyces fradiae Valine dehydrogenase P40176 [27]
pTEF1-NiCAR-tENO2 Entry vector Nocardia iowensis Carboxylic acid reductase Q6RKB1 [28]
pTEF1-NfCAR-tENO2 Entry vector Nocardia farcinica Carboxylic acid reductase Q5YY80 This study
pTEF1-MmCAR-tENO2 Entry vector Mycobacterium marinum Carboxylic acid reductase B2HN69 [46]
pTEF1-MsCAR-tENO2 Entry vector Mycobacterium smegmatis Carboxylic acid reductase L0IYJ8 [48]
pTEF2-BsSFP-tPGI1 Entry vector Bacillus subtilis Phosphopantetheinyl transferase P39135 [46]
pTEF2-MsPPTase-tPGI1 Entry vector Mycobacterium smegmatis Phosphopantetheinyl transferase L0ITG8 [48]
pPDC1-EcALR-tFBA1 Entry vector Escherichia coli Aldehyde reductase A0A094VUC2 This study
pURA3-ScURA3-tURA3 Entry vector Saccharomyces cerevisiae Uracil marker – –
ARS/CEN Entry vector Saccharomyces cerevisiae Origin of replication – –
pPYK1-tTEF1 2 micron Saccharomyces cerevisiae Vector only – –
pTEF2-tPGI1 ARS/CEN Saccharomyces cerevisiae Vector only – –
pPYK1-ScHOM3-R2-tTEF1 2 micron Saccharomyces cerevisiae Aspartate kinase (G425D) P10869 [31, 32]
pTEF2-EcGDH’-tPGI1 ARS/CEN Escherichia coli Glutamate dehydrogenase (K92 V/T195S) P00370 [26]
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The ORF encoding GLY1 was deleted by transforma-
tion of a PCR product encoding the marker LEU2 flanked 
by homologous regions upstream and downstream of the 
genomic GLY1 ORF. Successful deletion was confirmed 
by colony PCR.
The five pathway genes (BsILVa, EcGDH’, MmCAR, 
BsSFP, EcALR) were integrated by homologous recom-
bination of the same cassettes as used for the episomal 
expression plasmid (described before), except that the 
centromere region was exchanged with the homologous 
region on chromosome XI-2 (noncoding region between 
FAT3 and MTR2).
Transformation and cell growth
Yeast transformation was performed using the lithium 
acetate method described in [60]. Transformed clones 
were grown on agar plates prepared with selective SC 
drop out medium. Single colonies from the plates were 
inoculated into 3 mL of selective liquid SC medium and 
grown overnight at 30  °C in a shaker (160  rpm). Main 
Table 2 Strains
Strains Description Selection marker Replication origin/integration site
EVST20590 Contains expression cassettes of ScCHA1 and ScGDH1′ URA3 ARS/CEN
EVST20591 Contains expression cassettes of ScCHA1 and ScGDH3′ URA3 ARS/CEN
EVST20592 Contains expression cassettes of ScCHA1 and EcGDH’ URA3 ARS/CEN
EVST20879 Contains expression cassettes of ScCHA1 and BcLeuDH URA3 ARS/CEN
EVST20880 Contains expression cassettes of ScCHA1 and BfLeuDH URA3 ARS/CEN
EVST20881 Contains expression cassettes of ScGDH1′ and EcILVa URA3 ARS/CEN
EVST20882 Contains expression cassettes of ScGDH3′ and EcILVa URA3 ARS/CEN
EVST20883 Contains expression cassettes of EcGDH’ and EcILVa URA3 ARS/CEN
EVST20884 Contains expression cassettes of EcILVa and BcLeuDH URA3 ARS/CEN
EVST20885 Contains expression cassettes of EcILVa and BfLeuDH URA3 ARS/CEN
EVST21351 Contains expression cassettes of ScCHA1 and SfValDH URA3 ARS/CEN
EVST21352 Contains expression cassettes of EcILVa and SfValDH URA3 ARS/CEN
EVST21478 Contains expression cassettes of ScCHA1, EcGDH’, NiCAR, EcALR, 
and BsSFP
URA3 ARS/CEN
EVST21479 Contains expression cassettes of ScCHA1, EcGDH’, NfCAR, EcALR, 
and BsSFP
URA3 ARS/CEN
EVST21542 Control strain with empty entry vectors URA3 ARS/CEN
EVST22605 Contains expression cassettes of BsILVa and EcGDH’ URA3 ARS/CEN
EVST22606 Contains expression cassettes of ScILV1 and EcGDH’ URA3 ARS/CEN
EVST22608 Contains expression cassettes of SlTD and EcGDH’ URA3 ARS/CEN
EVST22609 Contains expression cassette of ScHOM3-R2 LEU2 2 micron




EVST22615 Contains expression cassettes of EcILVa, EcGDH’, MsCAR, 
MsPPTase, and EcALR
URA3 ARS/CEN
EVST22837 Contains expression cassette of SlTD and two EcGDH’ expression 
cassettes
URA3, HIS3 ARS/CEN both
EVST22857 Deletion of GLY1 ORF – –
EVST23406 Deletion of GLY1 ORF
Contains expression cassettes of BsILVa and EcGDH’
URA3 ARS/CEN
EVST23407 Deletion of GLY1 ORF
Contains expression cassettes of SlTD and EcGDH’
URA3 ARS/CEN
EVST24185 Contains expression cassettes of BsILVa, EcGDH’, MmCAR, EcALR, 
and BsSFP
URA3 ARS/CEN
EVST25556 Control strain with empty plasmid LEU2 2 micron
EVST25557 Contains expression cassettes of BsILVa, EcGDH’, and empty 
plasmid
URA3 (BsILVa, EcGDH’), LEU2 ARS/CEN (BsILVa, EcGDH’)
2 micron (empty plasmid)
EVST25635 Contains expression cassettes of SlTD, EcGDH’, and empty 
plasmid
URA3 (BsILVa, EcGDH’), HIS3 ARS/CEN both
EVST27022 Contains expression cassettes of BsILVa, EcGDH’, MmCAR, EcALR, 
and BsSFP
URA3 integrated into Chromosome XI-2
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cultures (25  mL in 250  mL shake flasks) for production 
of (S)-2-ABA were inoculated at a starting OD600 of 0.1, 
and kept on the shaker at 30  °C for 24–72  h. The main 
cultures for (S)-2-aminobutanol were carried out in 24 
deepwell plates (OD 0.1, 2.5  mL, 72  h, 30  °C, 300  rpm; 
Porvair, Norfolk, UK).
Extraction
Cell suspensions in 10 mL of growth medium were har-
vested by centrifugation at 4000 rpm for 5 min. One mil-
lilitre of the supernatant was removed for analysis. The 
remaining cell pellet was resuspended in 1 mL water and 
added to a 2 mL screw cap tube containing 500 µL glass 
beads (0.5 mm, Huberlab, Aesch, Switzerland). Cell lysis 
was performed by a precellys 24 bead beater (Bertin tech-
nologies, Aix-en-Provence Cedex, France) for 3 cycles for 
45 s with 60 s break. Cell debris was removed by centrifu-
gation (14,000 rpm, 5 min), and the supernatant was sub-
jected to analyses.
Analyses
Stock solutions of (R)- and (S)-2-aminobutyric acid, 
l-threonine, 2-ketobutyric acid, and 2-aminobutanol 
(1  g/L) were prepared in water. Calibration standards 
of those compounds were prepared in the range of 
31 μg/L–8 mg/L in water/acetonitrile 85:15.
Pellet extracts (150 μL) or supernatants (150 μL) were 
diluted into 850 μL of acetonitrile (in order to precipitate 
protein remainings), and centrifuged prior to injection.
Threonine, 2‑ketobutyric acid, 2‑aminobutyric acid, 
and 2‑aminobutanol analysis
Samples were injected into an Acquity UPLC-TQD 
(Waters), equipped with an Aquity UPLC BEH Amide 
1.7 μm 2.1 × 100 mm (Waters) column with two mobile 
phases. A: water with 10  mM ammonium formate and 
0.15% formic acid, and B: acetonitrile with 2 mM ammo-
nium formate and 0.05% formic acid. Separation was per-
formed with a gradient ranging from 85 to 82% of mobile 
phase B for 3 min then to 60% B in 1 min at a flow rate 
of 0.6 mL/min. Then a washing step at 60% B for 1 min, 
followed by a reconditioning step of 1 min at 85% B, was 
carried out. 2-Ketobutyric acid was detected with SIR 
mode following the mass 101.1 in ESI- with a cone volt-
age of 20  V. 2-Aminobutanol, 2-aminobutyric acid, and 
l-threonine were detected with MRM mode with the 
transitions 90.1 > 55, 104.1 > 58, 120 > 74 in ESI+ , cone 
voltages of 18, 16 and 16 V and collision voltages of 12 V 
for all compounds.
2‑Aminobutyric acid chiral analysis
Samples were injected on an Aquity UPLC-TQD 
(Waters) equipped with an Astec Chirobiotic T 
250  ×  4.6  mm column (Sigma) with water/methanol/
formic acid 30:70:0.02 isocratic mobile phase and 1 mL/
min flow during 16 min. (R)- and (S)-aminobutyric acid 
were detected with MRM mode with the transition 
104.1 > 58.0 in ESI+ , a cone voltage of 16 V and collision 
voltage of 12 V (Additional file 1: Figure S1).
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